{"id":"abrocitinib-200-mg-oral-tablet","safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)","action":"Avoid","effect":"Increased levels of abrocitinib"},{"drug":"P-glycoprotein inducers (e.g., rifampin, carbamazepine)","action":"Avoid","effect":"Decreased levels of abrocitinib"},{"drug":"Live vaccines","action":"Avoid","effect":"Reduced efficacy of vaccines"},{"drug":"Biologics (e.g., TNF-alpha inhibitors, IL-17 inhibitors)","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Immunosuppressants (e.g., azathioprine, cyclosporine)","action":"Monitor","effect":"Increased risk of infections"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"17.0%","placeboRate":"","totalAtRisk":489,"totalAffected":83,"trialsReporting":4},{"effect":"Headache","drugRate":"10.2%","placeboRate":"","totalAtRisk":489,"totalAffected":50,"trialsReporting":4},{"effect":"Acne","drugRate":"12.1%","placeboRate":"","totalAtRisk":380,"totalAffected":46,"trialsReporting":2},{"effect":"Dermatitis atopic","drugRate":"3.9%","placeboRate":"","totalAtRisk":461,"totalAffected":18,"trialsReporting":2},{"effect":"Vomiting","drugRate":"3.1%","placeboRate":"","totalAtRisk":479,"totalAffected":15,"trialsReporting":3},{"effect":"SARS-CoV-2 test positive","drugRate":"4.1%","placeboRate":"","totalAtRisk":362,"totalAffected":15,"trialsReporting":1},{"effect":"COVID-19","drugRate":"3.9%","placeboRate":"","totalAtRisk":362,"totalAffected":14,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"3.0%","placeboRate":"","totalAtRisk":461,"totalAffected":14,"trialsReporting":2},{"effect":"Blood creatine phosphokinase increased","drugRate":"3.9%","placeboRate":"","totalAtRisk":362,"totalAffected":14,"trialsReporting":1},{"effect":"Folliculitis","drugRate":"3.2%","placeboRate":"","totalAtRisk":372,"totalAffected":12,"trialsReporting":2},{"effect":"Herpes simplex","drugRate":"3.3%","placeboRate":"","totalAtRisk":362,"totalAffected":12,"trialsReporting":1},{"effect":"Fatigue","drugRate":"2.8%","placeboRate":"","totalAtRisk":362,"totalAffected":10,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"2.8%","placeboRate":"","totalAtRisk":362,"totalAffected":10,"trialsReporting":1},{"effect":"Natural killer cell count decreased","drugRate":"2.8%","placeboRate":"","totalAtRisk":362,"totalAffected":10,"trialsReporting":1},{"effect":"Dizziness","drugRate":"2.2%","placeboRate":"","totalAtRisk":461,"totalAffected":10,"trialsReporting":2},{"effect":"Herpes zoster","drugRate":"2.0%","placeboRate":"","totalAtRisk":461,"totalAffected":9,"trialsReporting":2},{"effect":"Oral herpes","drugRate":"2.5%","placeboRate":"","totalAtRisk":362,"totalAffected":9,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"2.1%","placeboRate":"","totalAtRisk":380,"totalAffected":8,"trialsReporting":2},{"effect":"Conjunctivitis","drugRate":"2.2%","placeboRate":"","totalAtRisk":362,"totalAffected":8,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"2.2%","placeboRate":"","totalAtRisk":362,"totalAffected":8,"trialsReporting":1},{"effect":"Weight increased","drugRate":"2.2%","placeboRate":"","totalAtRisk":362,"totalAffected":8,"trialsReporting":1},{"effect":"Epistaxis","drugRate":"2.2%","placeboRate":"","totalAtRisk":362,"totalAffected":8,"trialsReporting":1},{"effect":"Pruritus","drugRate":"4.3%","placeboRate":"","totalAtRisk":117,"totalAffected":5,"trialsReporting":2},{"effect":"Gastrooesophageal reflux disease","drugRate":"4.0%","placeboRate":"","totalAtRisk":99,"totalAffected":4,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"0.6%","placeboRate":"","totalAtRisk":362,"totalAffected":2,"trialsReporting":1},{"effect":"Incision site complication","drugRate":"11.1%","placeboRate":"","totalAtRisk":18,"totalAffected":2,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"1.0%","placeboRate":"","totalAtRisk":99,"totalAffected":1,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"1.0%","placeboRate":"","totalAtRisk":99,"totalAffected":1,"trialsReporting":1},{"effect":"Cough","drugRate":"1.0%","placeboRate":"","totalAtRisk":99,"totalAffected":1,"trialsReporting":1},{"effect":"Acneiform Eruption","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Sore throat","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Nasal Congestion","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"5.6%","placeboRate":"","totalAtRisk":18,"totalAffected":1,"trialsReporting":1},{"effect":"Hunger","drugRate":"5.6%","placeboRate":"","totalAtRisk":18,"totalAffected":1,"trialsReporting":1},{"effect":"Gastritis","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Asthma","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Rosacea","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Hypotension","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Eczema herpeticum","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Joint tuberculosis","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Pharyngitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Pyoderma","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Varicella","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Varicella zoster virus infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Viral infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Herpes Labialis","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1},{"effect":"Ear pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":18,"totalAffected":0,"trialsReporting":1},{"effect":"Feeling abnormal","drugRate":"0.0%","placeboRate":"","totalAtRisk":18,"totalAffected":0,"trialsReporting":1},{"effect":"Vessel puncture site haematoma","drugRate":"0.0%","placeboRate":"","totalAtRisk":18,"totalAffected":0,"trialsReporting":1},{"effect":"Vessel puncture site pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":18,"totalAffected":0,"trialsReporting":1}],"contraindications":["Antiplatelet therapies except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.","Avoid use of CIBINQO in patients with an active, serious infection including localized infections.","CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg","Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke."],"specialPopulations":{"Pregnancy":"Data are insufficient to evaluate drug-associated risk for major birth defects, miscarriage, or other adverse maternal outcomes. Impaired fertility in female rats was reversible 1 month after discontinuing abrocitinib. Abrocitinib secreted in milk of lactating rats. If a drug is present in animal milk, it is likely the drug will be present in human milk. Advise patients that breastfeeding is not recommended during treatment and for 1 days (~5-6 half-lives) after the last dose.","Geriatric use":"Not specified","Paediatric use":"Indicated for refractory moderate-to-severe atopic dermatitis (AD) in patients aged ≥12 years whose disease is not adequately controlled with topical therapies or phototherapy. Safety and efficacy not established in patients <12 years.","Renal impairment":"Patients on renal replacement therapy: Not studied; not recommended. Severe or end-stage renal disease (eGFR <29 mL/min): Not recommended. Moderate (eGFR 30-59 mL/min): 50 mg qDay initially; may double dose if adequate response not achieved. Mild (eGFR 60-89 mL/min): No dosage adjustment necessary.","Hepatic impairment":"Severe (Child-Pugh C): Not recommended. Mild or moderate (Child-Pugh A or B): No dose adjustment required."},"seriousAdverseEvents":[]},"company":"Pfizer","_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:34:07.136641+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:34:14.784701+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3655081/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:34:00.917007+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:34:16.154988+00:00"},"targetProtein":{"url":"https://www.uniprot.org/uniprot/A0A5F9ZHN8","method":"api_direct","source":"UniProt (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"uniprot","retrievedAt":"2026-04-19T21:33:54.931708+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:33:59.447964+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:34:16.154979+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:34:16.154975+00:00"},"commercial.annualRevenue":{"url":"","method":"deterministic","source":"SEC EDGAR 10-K","rawText":"$284M FY2025","confidence":0.8,"sourceType":"sec_edgar","retrievedAt":"2026-04-19T21:34:07.136680+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:34:16.154921+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:34:16.154948+00:00"}},"allNames":"abrocitinib 200 mg oral tablet","timeline":[],"aiSummary":"Abrocitinib 200 MG Oral Tablet, developed by Pfizer, holds a significant market position with $284M in revenue, targeting the JAK1 protein for the treatment of atopic dermatitis. Its oral administration offers a convenient alternative to injectable options like Dupixent, though it faces competition from other JAK inhibitors and topical treatments. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader adoption. Despite having no ongoing clinical trials, the drug's established revenue and targeted mechanism suggest a stable pipeline outlook focused on maintaining its current market share.","brandName":"Abrocitinib 200 MG Oral Tablet","isGeneric":true,"mechanism":{"target":"JAK1","novelty":"first-in-class","modality":"small molecule","drugClass":"JAK inhibitor","explanation":"Abrocitinib works by inhibiting the JAK1 protein, which plays a crucial role in the inflammatory response. This mechanism of action allows Abrocitinib to reduce inflammation and alleviate symptoms of atopic dermatitis. By targeting JAK1, Abrocitinib provides a novel approach to treating this condition.","oneSentence":"Abrocitinib 200 MG Oral Tablet is a small molecule that targets the JAK1 protein.","technicalDetail":"Abrocitinib 200 MG Oral Tablet is a potent and selective JAK1 inhibitor, with a half-life of approximately 5-7 hours. This allows for once-daily dosing and provides sustained therapeutic effects. The drug's mechanism of action is well-tolerated and has been shown to be effective in reducing symptoms of atopic dermatitis."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL3655081","maxPhase":"4.0","chirality":1,"parenteral":false,"availability":1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":1,"oralBioavailable":true},"commercial":{"revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":284,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"$21.2B","revenueCurrency":"USD","peakSalesEstimate":"$21.2B","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T10:48:50.281182","revenueExtractedBy":"revenue-sec"},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=abrocitinib-200-mg-oral-tablet","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-200-mg-oral-tablet","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:35:15.130020+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"competitors":[{"name":"Dupixent (dupilumab)","company":"Sanofi and Regeneron Pharmaceuticals","advantage":"Longer duration of action and alternative administration route (injection)"},{"name":"Ebglyss (lebrikizumab)","company":"Novartis Pharmaceuticals","advantage":"Alternative Janus kinase (JAK) inhibitor for atopic dermatitis treatment"},{"name":"Triamcinolone topical","company":"Various manufacturers","advantage":"Topical corticosteroid for localized treatment of atopic dermatitis"},{"name":"Clobetasol topical","company":"Various manufacturers","advantage":"High-potency topical corticosteroid for localized treatment of atopic dermatitis"},{"name":"Tacrolimus topical","company":"Various manufacturers","advantage":"Topical calcineurin inhibitor for localized treatment of atopic dermatitis"},{"name":"Dupilumab","company":"Sanofi and Regeneron Pharmaceuticals","advantage":"Alternative interleukin inhibitor for atopic dermatitis treatment"},{"name":"Betamethasone topical","company":"Various manufacturers","advantage":"Topical corticosteroid for localized treatment of atopic dermatitis"}],"genericName":"abrocitinib-200-mg-oral-tablet","indications":{"approved":[{"name":"Moderate to severe atopic dermatitis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"trialDetails":[],"_emaApprovals":[{"date":"","name":"Abrocitinib 200 MG Oral Tablet","status":"Authorised","regulator":"EMA"}],"molecularData":{"oral":true,"chemblId":"CHEMBL3655081","moleculeType":"Small molecule","molecularWeight":"323.42"},"targetProtein":{"url":"https://www.uniprot.org/uniprot/A0A5F9ZHN8","function":"Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor as well as interleukin (IL)-10 receptor. Kinase partner for the type I interferon receptor IFNAR2. In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins. Directly phosphorylates STAT proteins but also activates STAT signaling through the transact","geneName":"JAK1","organism":"Homo sapiens","uniprotId":"A0A5F9ZHN8","proteinName":"Tyrosine-protein kinase","sequenceLength":1110,"molecularWeight":127886,"subcellularLocation":"Endomembrane system"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3655081"},"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"INHIBITOR","targetChemblId":"CHEMBL2835","mechanismComment":null,"mechanismOfAction":"Tyrosine-protein kinase JAK1 inhibitor"}],"publicationCount":0,"_revenueScrapedAt":"2026-04-01 09:48:50.313664+00","recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"_genericFilersChecked":true,"structuredTrialResults":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":7,"withResults":4},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:35:15.130020+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}